Study on clinicopathological characteristics and prognosis of ER-low positive breast cancer using National Clinical Database-Breast Cancer Registry

Study on clinicopathological characteristics and prognosis of ER-low positive breast cancer using National Clinical Database-Breast Cancer Registry - ER low positive breast cancer in NCD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1030230687

Enrollment

200000

Registered

2024-03-11

Start date

2024-03-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer ER low positive breast cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Patients with primary breast cancer registered in the NCD 2. Patients with Stage I-III breast cancer who have undergone surgery

Exclusion criteria

Exclusion criteria: 1. non-invasive carcinoma (Tis) 2. Stage IV at diagnosis 3. Metastatic or recurrent breast cancer 4. Occult breast cancer (T0, TX) 5. HER2-positive breast cancer (immunostaining or FISH) 6. Male breast cancer 7. Synchronous or non-synchronous bilateral breast cancer 8. Preoperative radiotherapy cases

Design outcomes

Primary

Measure	Time frame
Disease-free survival, Breast Cancer Specific Survival, and Overall Survival in tumors with ER=10%, respectively Disease-free survival, Breast Cancer Specific Survival, and Overall Survival with and without perioperative endocrine therapy and chemotherapy in tumors with 1%<=ER<10	—

Secondary

Measure	Time frame
Disease-free survival, Breast Cancer Specific Survival, and Overall Survival with perioperative chemotherapy regimens (anthracycline alone, taxane alone, anthracycline + taxane) in tumors with 1%=10%, respectively	—

Contacts

Public ContactAiko Nagayama

Keio University School of Medicine

anagayama@keio.jp+81-3-3353-1211

Outcome results